AstraZeneca (LON:AZN) Rating Reiterated by JPMorgan Chase & Co.

AstraZeneca (LON:AZN)‘s stock had its “overweight” rating reaffirmed by equities research analysts at JPMorgan Chase & Co. in a research report issued to clients and investors on Tuesday, Marketbeat.com reports.

Other analysts also recently issued reports about the stock. Shore Capital reaffirmed a “buy” rating on shares of AstraZeneca in a report on Tuesday. Barclays reaffirmed an “overweight” rating and set a £125 ($158.87) price target on shares of AstraZeneca in a research report on Monday, April 8th. Berenberg Bank lifted their price objective on AstraZeneca from £120 ($152.52) to £130 ($165.23) and gave the company a “buy” rating in a research note on Friday, May 3rd. BMO Capital Markets restated an “outperform” rating on shares of AstraZeneca in a research note on Monday, February 12th. Finally, UBS Group reduced their price target on AstraZeneca from £107 ($135.99) to GBX 9,900 ($125.83) and set a “sell” rating for the company in a research report on Monday, February 12th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of £118 ($149.97).

AstraZeneca Price Performance

Shares of LON AZN opened at £123.70 ($157.22) on Tuesday. AstraZeneca has a 52 week low of GBX 9,461 ($120.25) and a 52 week high of £124.88 ($158.72). The business’s 50 day moving average price is £112.89 and its 200 day moving average price is £106.55. The company has a quick ratio of 0.59, a current ratio of 0.89 and a debt-to-equity ratio of 92.51. The firm has a market cap of £191.73 billion, a P/E ratio of 3,862.50, a P/E/G ratio of 0.95 and a beta of 0.16.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.